ArticleScientific reports2025
A migrasome-related LncRNA signatures for predicting prognosis and immunotherapeutic response in colorectal cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Migrasome has recently been reported to regulate cell-cell communication in tumor progression. But the function of migrasome in CRC, especially its prognostic potential and association with long non-coding RNAs and tumor microenvironment has yet to be fully explored. Migrasome-related lncRNAs were identified based on transcriptome data from 650 CRC patients in the TCGA COREAD cohort. A prognostic signature was developed via the least absolute shrinkage and selection operator algorithm and Cox regression. The multimodal predicting model for prognosis of CRC patients was constructed and validated through Kaplan-Meier survival, ROC curve analysis, and nomogram construction. Patients were divided into high- and low-risk groups according to their prognostic signature and functional enrichment, immune cell infiltration, immunotherapy efficacy, and drug sensitivity analyses were performed to characterize their variation. Ten migrasome-related lncRNAs were identified and used to construct a prognostic risk score that effectively stratified patients into high- and low-risk groups, demonstrating significant differences in overall survival (P < 0.001) and survival-related ROC curve analysis. A nomogram based on the multimodal predicting model was constructed with robust calibration curves. The transcriptional variation between high-risk and low-risk patients were mainly associated with signaling receptor activator activity, receptor ligand activity and cytokine-cytokine receptor interaction. High-risk patients exhibited reduced immune cell infiltration and higher potential for immune escape. In addition, drug sensitivity screening revealed that high-risk patients were more likely to resist current targeted drugs including PLX-4720 and JAK-8517 than low-risk patients. This study identifies a novel migrasome-related lncRNA signature as a reliable prognostic tool for CRC, highlighting its potential in patient stratification and personalized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.